U.S. markets closed

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.73+0.42 (+1.97%)
At close: 04:00PM EDT
22.01 +0.28 (+1.29%)
After hours: 07:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close21.31
Bid21.77 x 1200
Ask22.20 x 900
Day's Range21.16 - 21.89
52 Week Range13.59 - 27.45
Avg. Volume400,237
Market Cap1.117B
Beta (5Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-4.67
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ARQT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcutis Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more

    Mercury Systems and GMS Stock See Action From Activist Investors

    Starboard Value and Jana Partners reached a deal for seats on defense contractor Mercury Systems’ board. Coliseum Capital lifted its stake in building-products distributor GMS.

  • Motley Fool

    Could 2023 Be a Breakout Year for This Pharma Stock?

    A Food and Drug Administration (FDA) approval for a highly anticipated treatment is the kind of news that can make a company's stock skyrocket, even during a bear market -- like the one we're in now. One company hoping for such success is Arcutis Biotherapeutics (NASDAQ: ARQT). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff-like flakes, on the face and scalp.

  • GlobeNewswire

    Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

    Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P<0.0001) More than 50% of patients treated with roflumilast foam achieved an IGA score of clear at week eight Roflumilast foam was well-tolerated with a favorable safety and tolerability profile Data further support the potential of roflumilast foam as a best-in-class, once-daily, non-steroidal topical t